Eli Lilly的试验发现,在没有糖尿病的肥胖成年人中,如果与生活方式的改变相结合,不患糖尿病的肥胖成人体重显著下降。 Eli Lilly's trial found orforglipron caused significant weight loss in obese adults without diabetes when combined with lifestyle changes.

伊利利利公司的ATTAIN-1第3期试验显示, orforglipron是一种实验性口服GLP-1受体激动剂,导致肥胖或超重的成年人显著减肥,且没有糖尿病. Eli Lilly's Phase 3 ATTAIN-1 trial showed that orforglipron, an investigational oral GLP-1 receptor agonist, led to significant weight loss in adults with obesity or overweight with weight-related health issues, without diabetes. 所有三剂-6毫克、12毫克和36毫克-优于安慰剂,在72周后减少了体重。 All three doses—6 mg, 12 mg, and 36 mg—outperformed placebo in reducing body weight after 72 weeks. 试验是这一组人第3阶段研究的第一阶段,目的是在锻炼和健康饮食的同时测试或forglipron,而不是降低卡路里饮食。 The trial is the first Phase 3 study in this group to test orforglipron alongside exercise and a healthy diet, not a reduced-calorie diet. 超过4 500名参与者加入了莉莉的全球发展方案,今年预期会取得更多成果。 Over 4,500 participants have joined Lilly’s global development program, with more results expected this year.